These recommendations, the group emphasized, do not include patients with a history of CVD or those who are already taking aspirin for another reason.

The recall is focused on a single batch distributed from December 2021 to March 2022.

An updated look at patients treated with Medtronic's renal denervation system was presented at ACC.22 and simultaneously published in The Lancet. 

Steven E. Nissen, MD, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at the Cleveland Clinic, was the lead author on the Apollo Trial, a late-breaking ACC.22 study evaluating the effectiveness of an mRNA drug to suppress lipoprotein(a).

“There is a need for awareness of this higher risk of CVD, and further research is warranted to identify strategies that mitigate cardiovascular risk during notable political events,” researchers explained. 

The new analysis, published in the Journal of the American Heart Association, included patient data from the last three decades. 

The research was presented in South Korea at a two-day event hosted by the American College of Cardiology and Korean Society of Cardiology.

The associations between schizophrenia or bipolar disorder and cardiovascular mortality have grown in recent decades.

The authors hope their findings could lead to earlier diagnoses and improvements in patient care.